Comment traite-t-on les patients qui ont été réfractaires aux 3 classes thérapeutiques (IMiDs, PI, anticorps monoclonal) ou penta-exposés (2 IMiDs, 2 PIs, anticorps monoclonal) et avec un myélome avancé ?

Dr BELHADJ Karim

mercredi 2 octobre 2024 19:00

Inscription

⌛ Vous arrivez trop tard, malheureusement cet événement est terminé...

OSÉUS Médical
1 rue des Vergers
Bâtiment 6 – Hall D
69760 Limonest
France

LinkedIn
Twitter

Nos Réunions
Qui sommes-nous ?
Contact
Industries de la santé
CONDITIONS GENERALES D’UTILISATION
POLITIQUE DE PROTECTION DES DONNEES PERSONNELLES
Mentions légales

Nous utilisons des cookies pour vous fournir une meilleure expérience. En cliquant sur accepter, vous acceptez l'utilisation de tous les cookies.

Réglages Accepter

Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Toujours activé

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Enregistrer & appliquer